Sector News

Busy AstraZeneca inks yet another big COVID vaccine deal, this time with EU

August 17, 2020
Life sciences

As Johnson & Johnson, Sanofi and GlaxoSmithKline move ahead in advanced COVID-19 vaccine supply negotiations with the EU, AstraZeneca has signed into the union’s first finalized agreement.

The drugmaker on Friday pledged 400 million doses of its investigational COVID-19 vaccine, AZD1222, at no profit for EU countries. The deal builds on a prior pact with the Inclusive Vaccines Alliance, which is led by Germany, France, Italy and the Netherlands.

Under the new agreement, EU member countries can “access the vaccine in an equitable manner,” AZ says, and can redirect vaccines to other countries in Europe.

Meanwhile, Johnson & Johnson and a partnership between Sanofi and GlaxoSmithKline are in advanced in talks with the EU to supply 200 million doses and 300 million doses, respectively. Johnson & Johnson on Thursday said it’s concluded exploratory talks and is entering contract negotiations. The EU concluded early talks with Sanofi and GlaxoSmithKline late last month.

AstraZeneca’s vaccine is the farthest along in testing among that group of pharma giants. The company recently kicked off late-stage testing, and with success, could begin deliveries in late 2020. Johnson & Johnson has started human testing on its shot, while the Sanofi/GSK partnership team is in preclinical stages.

Aside from EU talks, all of the companies have inked major partnerships with the U.S. and the U.K., as well. AstraZeneca’s Friday deal is larger than other supply arrangements inked with governments to date, but it isn’t as big as the company’s licensing agreement with the Serum Institute of India for 1 billion doses to boost access in low- and middle-income countries

The drugmaker has also signed deals to help make the vaccine available in Japan, Russia, China, Mexico, Argentina and elsewhere.

But delivery of any doses will depend on successful late-stage testing. The company has started a phase 2/3 trial in the U.K., but it hasn’t yet completed enrollment, according to Politico reporter Zach Brennan.

By: Eric Sagonowsky

Source: Fierce Pharma

comments closed

Related News

June 24, 2022

Echosens and Novo Nordisk announce partnership to increase awareness and advance early diagnosis of NASH

Life sciences

Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.

June 24, 2022

argenx receives positive CHMP opinion for Efgartigimod for the treatment of adult patients with Generalized Myasthenia Gravis in Europe

Life sciences

Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).

June 24, 2022

Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push

Life sciences

Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).